-
1
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
DOI 10.1056/NEJMoa041318
-
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351, 1513-1520. (Pubitemid 39315318)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.A.3
Lara Jr., P.N.4
Jones, J.A.5
Taplin, M.E.6
Burch, P.A.7
Berry, D.8
Moinpour, C.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
2
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
DOI 10.1056/NEJMoa040720
-
Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351, 1502-1512. (Pubitemid 39315317)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
3
-
-
24744471465
-
Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy
-
DOI 10.1002/jcb.20460
-
Burnstein K (2005). Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95, 657-669. (Pubitemid 41420154)
-
(2005)
Journal of Cellular Biochemistry
, vol.95
, Issue.4
, pp. 657-669
-
-
Burnstein, K.L.1
-
4
-
-
12344338583
-
Expression and function of androgen receptor coactivators in prostate cancer
-
DOI 10.1016/j.jsbmb.2004.10.003, PII S0960076004003668, Steroids and Prostate Cancer
-
Culig Z, Comuzzi B, Steiner H, Bartsch G, and Hobisch A (2004). Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92, 265-271. (Pubitemid 40128247)
-
(2004)
Journal of Steroid Biochemistry and Molecular Biology
, vol.92
, Issue.4
, pp. 265-271
-
-
Culig, Z.1
Comuzzi, B.2
Steiner, H.3
Bartsch, G.4
Hobisch, A.5
-
5
-
-
4944246790
-
Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer
-
DOI 10.1677/erc.1.00525
-
Scher HI, Buchanan G, Gerald W, Butler LM, and Tilley WD (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11, 459-476. (Pubitemid 39331277)
-
(2004)
Endocrine-Related Cancer
, vol.11
, Issue.3
, pp. 459-476
-
-
Scher, H.I.1
Buchanan, G.2
Gerald, W.3
Butler, L.M.4
Tilley, W.D.5
-
6
-
-
29144508739
-
Secondary hormonal therapy for advanced prostate cancer
-
DOI 10.1016/S0022-5347(05)00034-0, PII S0022534705000340
-
Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, and Belldegrun AS (2006). Secondary hormonal therapy for advanced prostate cancer. J Urol 175, 27-34. (Pubitemid 41797079)
-
(2006)
Journal of Urology
, vol.175
, Issue.1
, pp. 27-34
-
-
Lam, J.S.1
Leppert, J.T.2
Vemulapalli, S.N.3
Shvarts, O.4
Belldegrun, A.S.5
-
7
-
-
27644452640
-
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
-
Titus MA, Schell MJ, Lih FB, Tomer KB, and Mohler JL (2005). Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11, 4653-4657.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4653-4657
-
-
Titus, M.A.1
Schell, M.J.2
Lih, F.B.3
Tomer, K.B.4
Mohler, J.L.5
-
8
-
-
49249119358
-
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
-
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, and Nelson PS (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68, 4447-4454.
-
(2008)
Cancer Res
, vol.68
, pp. 4447-4454
-
-
Montgomery, R.B.1
Mostaghel, E.A.2
Vessella, R.3
Hess, D.L.4
Kalhorn, T.F.5
Higano, C.S.6
True, L.D.7
Nelson, P.S.8
-
9
-
-
51049098138
-
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
-
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, and Nelson CC (2008). Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68, 6407-6415.
-
(2008)
Cancer Res
, vol.68
, pp. 6407-6415
-
-
Locke, J.A.1
Guns, E.S.2
Lubik, A.A.3
Adomat, H.H.4
Hendy, S.C.5
Wood, C.A.6
Ettinger, S.L.7
Gleave, M.E.8
Nelson, C.C.9
-
10
-
-
53749090666
-
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven
-
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven. J Clin Oncol 26, 4563-4571.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4563-4571
-
-
Attard, G.1
Reid, A.H.2
Yap, T.A.3
Raynaud, F.4
Dowsett, M.5
Settatree, S.6
Barrett, M.7
Parker, C.8
Martins, V.9
Folkerd, E.10
-
11
-
-
53349101498
-
Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β- hydroxy-17-(1H- benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
-
Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, and Brodie AM (2008). Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β- hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7, 2348-2357.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2348-2357
-
-
Vasaitis, T.1
Belosay, A.2
Schayowitz, A.3
Khandelwal, A.4
Chopra, P.5
Gediya, L.K.6
Guo, Z.7
Fang, H.B.8
Njar, V.C.9
Brodie, A.M.10
-
12
-
-
63849108231
-
Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235)
-
Trauger R, Corey E, Bell D, White S, Garsd A, Stickney D, Reading C, and Frincke J (2009). Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235). Br J Cancer 100, 1068-1072.
-
(2009)
Br J Cancer
, vol.100
, pp. 1068-1072
-
-
Trauger, R.1
Corey, E.2
Bell, D.3
White, S.4
Garsd, A.5
Stickney, D.6
Reading, C.7
Frincke, J.8
-
13
-
-
0038475987
-
LuCaP 35: A new model of prostate cancer progression to androgen independence
-
Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, and Vessella RL (2003). LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 55, 239-246.
-
(2003)
Prostate
, vol.55
, pp. 239-246
-
-
Corey, E.1
Quinn, J.E.2
Buhler, K.R.3
Nelson, P.S.4
Macoska, J.A.5
True, L.D.6
Vessella, R.L.7
-
14
-
-
0034234571
-
LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis
-
DOI 10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L
-
Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, and Chung LW (2000). LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91-103. (Pubitemid 30419183)
-
(2000)
Prostate
, vol.44
, Issue.2
, pp. 91-103
-
-
Thalmann, G.N.1
Sikes, R.A.2
Wu, T.T.3
Degeorges, A.4
Chang, S.-M.5
Ozen, M.6
Pathak, S.7
Chung, L.W.K.8
-
15
-
-
33749856315
-
Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes
-
DOI 10.1593/neo.06328
-
Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, and Corey E (2006). Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8, 862-878. (Pubitemid 44564842)
-
(2006)
Neoplasia
, vol.8
, Issue.10
, pp. 862-878
-
-
Coleman, I.M.1
Kiefer, J.A.2
Brown, L.G.3
Pitts, T.E.4
Nelson, P.S.5
Brubaker, K.D.6
Vessella, R.L.7
Corey, E.8
-
16
-
-
0036604237
-
Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells
-
DOI 10.1002/pros.10091
-
Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, and Vessella RL (2002). Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52, 20-33. (Pubitemid 34553189)
-
(2002)
Prostate
, vol.52
, Issue.1
, pp. 20-33
-
-
Corey, E.1
Quinn, J.E.2
Bladou, F.3
Brown, L.G.4
Roudier, M.P.5
Brown, J.M.6
Buhler, K.R.7
Vessella, R.L.8
-
17
-
-
12444300160
-
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft
-
Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, and Corey E (2004). The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 21, 381-387.
-
(2004)
Clin Exp Metastasis
, vol.21
, pp. 381-387
-
-
Kiefer, J.A.1
Vessella, R.L.2
Quinn, J.E.3
Odman, A.M.4
Zhang, J.5
Keller, E.T.6
Kostenuik, P.J.7
Dunstan, C.R.8
Corey, E.9
-
18
-
-
7444249518
-
Metastases of prostate cancer express estrogen receptor-beta
-
DOI 10.1016/j.urology.2004.05.036, PII S0090429504006922
-
Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, and Corey E (2004). Metastases of prostate cancer express estrogen receptor-beta. Urology 64, 814-820. (Pubitemid 39446081)
-
(2004)
Urology
, vol.64
, Issue.4
, pp. 814-820
-
-
Lai, J.S.1
Brown, L.G.2
True, L.D.3
Hawley, S.J.4
Etzioni, R.B.5
Higano, C.S.6
Ho, S.-M.7
Vessella, R.L.8
Corey, E.9
-
19
-
-
0026536536
-
Adrenal glands of mouse and rat do not synthesize androgens
-
vanWeerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, and Schroder FH (1992). Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 50, 857-861.
-
(1992)
Life Sci
, vol.50
, pp. 857-861
-
-
VanWeerden, W.M.1
Bierings, H.G.2
Van Steenbrugge, G.J.3
De Jong, F.H.4
Schroder, F.H.5
-
20
-
-
0034652723
-
Androgen receptor mutations in prostate cancer
-
Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, et al. (2000). Androgen receptor mutations in prostate cancer. Cancer Res 60, 944-949.
-
(2000)
Cancer Res
, vol.60
, pp. 944-949
-
-
Marcelli, M.1
Ittmann, M.2
Mariani, S.3
Sutherland, R.4
Nigam, R.5
Murthy, L.6
Zhao, Y.7
DiConcini, D.8
Puxeddu, E.9
Esen, A.10
-
21
-
-
34250901788
-
Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells
-
Carey AM, Pramanik R, Nicholson LJ, Dew TK, Martin FL, Muir GH, and Morris JD (2007). Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells. Int J Cancer 121, 520-527.
-
(2007)
Int J Cancer
, vol.121
, pp. 520-527
-
-
Carey, A.M.1
Pramanik, R.2
Nicholson, L.J.3
Dew, T.K.4
Martin, F.L.5
Muir, G.H.6
Morris, J.D.7
-
22
-
-
70350738817
-
Abiraterone suppresses castration resistant human prostate cancer growth in the absence of testicular and adrenal androgens
-
Abstract
-
Montgomery RB, Mostaghel E, Nelson PS, Marck B, Nguyen H, and Vessella RL (2009). Abiraterone suppresses castration resistant human prostate cancer growth in the absence of testicular and adrenal androgens. Advances in Prostate Cancer, AACR Conference, January 2009. San Diego, CA, Abstract.
-
(2009)
Advances in Prostate Cancer, AACR Conference, January 2009. San Diego, CA
-
-
Montgomery, R.B.1
Mostaghel, E.2
Nelson, P.S.3
Marck, B.4
Nguyen, H.5
Vessella, R.L.6
|